Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 489

1.

Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV.

Zeitlin L, Rauch F, Plotkin H, Glorieux FH.

Pediatrics. 2003 May;111(5 Pt 1):1030-6.

PMID:
12728084
[PubMed - indexed for MEDLINE]
2.

Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.

Land C, Rauch F, Travers R, Glorieux FH.

Bone. 2007 Mar;40(3):638-44. Epub 2006 Nov 28.

PMID:
17127117
[PubMed - indexed for MEDLINE]
3.

Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement.

Letocha AD, Cintas HL, Troendle JF, Reynolds JC, Cann CE, Chernoff EJ, Hill SC, Gerber LH, Marini JC.

J Bone Miner Res. 2005 Jun;20(6):977-86. Epub 2005 Jan 18.

PMID:
15883638
[PubMed - indexed for MEDLINE]
4.

The effect of cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta type V.

Zeitlin L, Rauch F, Travers R, Munns C, Glorieux FH.

Bone. 2006 Jan;38(1):13-20. Epub 2005 Sep 12.

PMID:
16162424
[PubMed - indexed for MEDLINE]
5.

Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment.

Land C, Rauch F, Munns CF, Sahebjam S, Glorieux FH.

Bone. 2006 Oct;39(4):901-6. Epub 2006 May 26.

PMID:
16730480
[PubMed - indexed for MEDLINE]
6.

Effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta: clinical and histomorphometric outcome.

Munns CF, Rauch F, Travers R, Glorieux FH.

J Bone Miner Res. 2005 Jul;20(7):1235-43. Epub 2005 Feb 21.

PMID:
15940378
[PubMed - indexed for MEDLINE]
7.

Pamidronate treatment of less severe forms of osteogenesis imperfecta in children.

Zacharin M, Kanumakala S.

J Pediatr Endocrinol Metab. 2004 Nov;17(11):1511-7.

PMID:
15570988
[PubMed - indexed for MEDLINE]
8.

Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy.

Rauch F, Plotkin H, Zeitlin L, Glorieux FH.

J Bone Miner Res. 2003 Apr;18(4):610-4.

PMID:
12674321
[PubMed - indexed for MEDLINE]
9.

Long-bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfecta.

Rauch F, Cornibert S, Cheung M, Glorieux FH.

Bone. 2007 Apr;40(4):821-7. Epub 2007 Jan 12.

PMID:
17223617
[PubMed - indexed for MEDLINE]
10.

Intravenous pamidronate in osteogenesis imperfecta type VII.

Cheung MS, Glorieux FH, Rauch F.

Calcif Tissue Int. 2009 Mar;84(3):203-9. doi: 10.1007/s00223-008-9211-9. Epub 2009 Jan 10.

PMID:
19137231
[PubMed - indexed for MEDLINE]
11.

Cyclic pamidronate therapy in children with osteogenesis imperfecta: results of treatment and follow-up after discontinuation.

Andiran N, Alikasifoglu A, Gonc N, Ozon A, Kandemir N, Yordam N.

J Pediatr Endocrinol Metab. 2008 Jan;21(1):63-72.

PMID:
18404974
[PubMed - indexed for MEDLINE]
12.
13.

Cyclical intravenous pamidronate treatment affects metaphyseal modeling in growing patients with osteogenesis imperfecta.

Land C, Rauch F, Glorieux FH.

J Bone Miner Res. 2006 Mar;21(3):374-9. Epub 2005 Dec 19.

PMID:
16491284
[PubMed - indexed for MEDLINE]
14.

Osteogenesis imperfecta: anthropometric, skeletal and mineral metabolic effects of long-term intravenous pamidronate therapy.

Vallo A, Rodriguez-Leyva F, Rodríguez Soriano J.

Acta Paediatr. 2006 Mar;95(3):332-9.

PMID:
16497645
[PubMed - indexed for MEDLINE]
15.

Effect of cyclical intravenous pamidronate therapy in children with osteogenesis imperfecta. Open-label study in seven patients.

Giraud F, Meunier PJ.

Joint Bone Spine. 2002 Oct;69(5):486-90.

PMID:
12477233
[PubMed - indexed for MEDLINE]
16.

Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta.

DiMeglio LA, Peacock M.

J Bone Miner Res. 2006 Jan;21(1):132-40. Epub 2005 Oct 17.

PMID:
16355282
[PubMed - indexed for MEDLINE]
18.

Bone densitometry in pediatric patients treated with pamidronate.

Grissom LE, Kecskemethy HH, Bachrach SJ, McKay C, Harcke HT.

Pediatr Radiol. 2005 May;35(5):511-7. Epub 2005 Jan 18.

PMID:
15655696
[PubMed - indexed for MEDLINE]
19.

Rapid increase in grip force after start of pamidronate therapy in children and adolescents with severe osteogenesis imperfecta.

Montpetit K, Plotkin H, Rauch F, Bilodeau N, Cloutier S, Rabzel M, Glorieux FH.

Pediatrics. 2003 May;111(5 Pt 1):e601-3.

PMID:
12728117
[PubMed - indexed for MEDLINE]
20.

Pamidronate does not adversely affect bone intrinsic material properties in children with osteogenesis imperfecta.

Weber M, Roschger P, Fratzl-Zelman N, Schöberl T, Rauch F, Glorieux FH, Fratzl P, Klaushofer K.

Bone. 2006 Sep;39(3):616-22. Epub 2006 Apr 27.

PMID:
16644299
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk